Skip to Main Content
Newsroom
Get in Touch
LinkedIn
Editas Medicine Linkedin
Research and Pipeline
CRISPR Gene Editing
For Patients
Who We Are
Join Our Team
Investors
Newsroom
Get in Touch
LinkedIn
Purchasing Policy Terms and Conditions
+
-
Editas Newsroom
Oct
1
Editas Medicine to Participate in Upcoming Investor Conference
Sep
11
Editas Medicine Announces U.S. Patent and Trademark Office Grants the Broad Institute Priority Benefit in CRISPR Interference
Sep
4
Editas Medicine to Participate in Upcoming Investor Conferences